Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Effects of 17β-estradiol and tamoxifen on gastric cancer cell proliferation and apoptosis and ER-α36 expression.

Wang X, Chen Q, Huang X, Zou F, Fu Z, Chen Y, Li Y, Wang Z, Liu L.

Oncol Lett. 2017 Jan;13(1):57-62. doi: 10.3892/ol.2016.5424.

2.

Discovery at the interface: Toward novel anti-proliferative agents targeting human estrogen receptor/S100 interactions.

Lee DH, Asare BK, Rajnarayanan RV.

Cell Cycle. 2016 Oct 17;15(20):2806-18. doi: 10.1080/15384101.2016.1220460.

PMID:
27580430
3.

Endocrine-disrupting chemicals and uterine fibroids.

Katz TA, Yang Q, Treviño LS, Walker CL, Al-Hendy A.

Fertil Steril. 2016 Sep 15;106(4):967-77. doi: 10.1016/j.fertnstert.2016.08.023. Review.

PMID:
27553264
4.

Tamoxifen Resistance: Emerging Molecular Targets.

Rondón-Lagos M, Villegas VE, Rangel N, Sánchez MC, Zaphiropoulos PG.

Int J Mol Sci. 2016 Aug 19;17(8). pii: E1357. doi: 10.3390/ijms17081357. Review.

5.

Early Life Adverse Environmental Exposures Increase the Risk of Uterine Fibroid Development: Role of Epigenetic Regulation.

Yang Q, Diamond MP, Al-Hendy A.

Front Pharmacol. 2016 Mar 1;7:40. doi: 10.3389/fphar.2016.00040. Review.

6.

The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance.

Zarif JC, Miranti CK.

Cell Signal. 2016 May;28(5):348-56. doi: 10.1016/j.cellsig.2016.01.013. Review.

7.

Nodes-and-connections RNAi knockdown screening: identification of a signaling molecule network involved in fulvestrant action and breast cancer prognosis.

Miyoshi N, Wittner BS, Shioda K, Hitora T, Ito T, Ramaswamy S, Isselbacher KJ, Sgroi DC, Shioda T.

Oncogenesis. 2015 Oct 19;4:e172. doi: 10.1038/oncsis.2015.32.

8.

Signaling Pathways in Leiomyoma: Understanding Pathobiology and Implications for Therapy.

Borahay MA, Al-Hendy A, Kilic GS, Boehning D.

Mol Med. 2015 Apr 13;21:242-56. doi: 10.2119/molmed.2014.00053. Review.

9.

Evaluating the evidence for targeting FOXO3a in breast cancer: a systematic review.

Taylor S, Lam M, Pararasa C, Brown JE, Carmichael AR, Griffiths HR.

Cancer Cell Int. 2015 Jan 24;15(1):1. doi: 10.1186/s12935-015-0156-6.

10.
11.

Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.

Ribeiro JR, Freiman RN.

J Steroid Biochem Mol Biol. 2014 Sep;143:160-73. doi: 10.1016/j.jsbmb.2014.02.010. Review.

12.

Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase.

Yeh WL, Shioda K, Coser KR, Rivizzigno D, McSweeney KR, Shioda T.

PLoS One. 2013 Apr 4;8(4):e60889. doi: 10.1371/journal.pone.0060889.

13.

The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer.

Aust S, Horak P, Pils D, Pils S, Grimm C, Horvat R, Tong D, Schmid B, Speiser P, Reinthaller A, Polterauer S.

BMC Cancer. 2013 Mar 14;13:115. doi: 10.1186/1471-2407-13-115.

14.

Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.

García-Becerra R, Santos N, Díaz L, Camacho J.

Int J Mol Sci. 2012 Dec 20;14(1):108-45. doi: 10.3390/ijms14010108. Review.

15.

Distribution and posttranslational modification of synaptic ERα in the adult female rat hippocampus.

Tabatadze N, Smejkalova T, Woolley CS.

Endocrinology. 2013 Feb;154(2):819-30. doi: 10.1210/en.2012-1870.

16.

A mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer model.

Pritchard JE, Dillon PM, Conaway MR, Silva CM, Parsons SJ.

Oncology. 2012;83(6):305-20. doi: 10.1159/000341394.

17.

Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.

Fan P, McDaniel RE, Kim HR, Clagett D, Haddad B, Jordan VC.

Eur J Cancer. 2012 Dec;48(18):3488-98. doi: 10.1016/j.ejca.2012.04.020.

18.
19.

Breaking the cycle: An insight into the role of ERα in eukaryotic cell cycles.

Moghadam SJ, Hanks AM, Keyomarsi K.

J Carcinog. 2011;10:25. doi: 10.4103/1477-3163.90440.

20.

Cytoplasmic estrogen receptor in breast cancer.

Welsh AW, Lannin DR, Young GS, Sherman ME, Figueroa JD, Henry NL, Ryden L, Kim C, Love RR, Schiff R, Rimm DL.

Clin Cancer Res. 2012 Jan 1;18(1):118-26. doi: 10.1158/1078-0432.CCR-11-1236.

Supplemental Content

Support Center